Faculty

Main navigation

2023 Bernice Grafstein Lecture in Neuroscience presents Dr. Marina Picciotto

Published: 16 October 2023

The Integrated Program in Neuroscience (IPN) invites Dr. Marina Picciotto is give the 2023 Bernice Grafstein Lecture in Neuroscience. Dr. Picciotto is the Charles B. G. Murphy Professor of...

Read more about 2023 Bernice Grafstein Lecture in Neuroscience presents Dr. Marina Picciotto

AI analysis of healthcare records reveals key factors in autism diagnosis

Published: 26 March 2025

Scientists argue the criteria we use for diagnosing autism may need revision...

Read more about AI analysis of healthcare records reveals key factors in autism diagnosis

Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

Published: 14 March 2025

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation...

Read more about Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

Project to create AI model for ALS receives G茅nome Qu茅bec funding

Published: 17 March 2025

$400,000 will fuel public-private collaboration to discover new disease biomarkers...

Read more about Project to create AI model for ALS receives G茅nome Qu茅bec funding

Six principal investigators from The Neuro receive CIHR grants

Published: 10 February 2025

Projects include important research on Parkinson鈥檚, glioblastoma and dementia 聽

Read more about Six principal investigators from The Neuro receive CIHR grants

Genetic sequencing project receives more than $8 million in funding

Published: 18 March 2025

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians...

Read more about Genetic sequencing project receives more than $8 million in funding

Latest Alzheimer鈥檚 drug shown less effective in females than males

Published: 18 March 2025

Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...